Evidence map›Paper›PMID 30423391›Full record

GuidelineJournal of the American College of Cardiology2019

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Scott M Grundy, Neil J Stone, Alison L Bailey, Craig Beam, Kim K Birtcher, Roger S Blumenthal, Lynne T Braun, Sarah de Ferranti, Joseph Faiella-Tommasino, Daniel E Forman and 14 more

Erratum issued 3 registry-linked trialsAbstract readPractice Guideline
PubMed Publisher
In one paragraph

Guideline in Journal of the American College of Cardiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 3 registered trials, which are not on this map. Cited by 810 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
810citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04826354 phase4completedstarted 2021, after this paper: background citation

Effects of High-dose StAtin Versus Low-dose Statin Plus Ezetimibe on Statin-Associated Muscle Symptoms & on Reaching Target LDL-C Levels Among Elderly Patients With Atherosclerotic Cardiovascular Disease

Ran2021Enrolled582Registered outcomes11Posted comparisons0ConditionsAtheroscleroses, CoronaryArmsRosuvastatin, rosuvastatin and ezetimibe
PMID 28249067PMID 30403574PMID 28007331PMID 28304224PMID 26039521PMID 28444290PMID 16453090PMID 22686958PMID 29020411PMID 30580575PMID 16214597PMID 25770315other papers from this trial
Open the trial in the graph
NCT04400409 nacompletednot on this mapstarted 2020, after this paper: background citation

Implementation of Vascular Care Team to Improve Medical Management of Peripheral Arterial Disease (PAD) Patients

TypeinterventionalSponsorColorado Prevention CenterRan2020 to 2023Enrolled166ConditionsPeripheral Artery DiseaseArmsIntervention A - Vascular Care + site 6MWT administration, Intervention B - Standard Care + site 6MWT administration, Intervention A - Vascular Care + CPC EQuIP 6MWT administration, Intervention B - Standard Care + CPC EQuIP 6MWT administration
NCT06471036 narecruitingnot on this mapstarted 2024, after this paper: background citation

Test 2 Treat: A Randomized Implementation Trial to Improve LDL-C Management After Hospitalization for ASCVD (Atherosclerotic Cardiovascular Disease)

TypeinterventionalSponsorDuke UniversityRan2024 to 2027Enrolled400ConditionsASCVD, LDL-CArmsCare Champion Intervention
3 · Its place in the literature

Who cites it

810 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Efficacy and Safety of Ongericimab in Chinese Patients with Hypercholesterolemia: A Meta-analysis of Randomized Controlled Trials.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Guideline
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Observational

750 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors.

Scott M Grundy
Neil J Stone
Alison L Bailey
Craig Beam
Kim K Birtcher
Roger S Blumenthal
Lynne T Braun
Sarah de Ferranti
Joseph Faiella-Tommasino
Daniel E Forman
Ronald Goldberg
Paul A Heidenreich
Mark A Hlatky
Daniel W Jones
Donald Lloyd-Jones
Nuria Lopez-Pajares
Chiadi E Ndumele
Carl E Orringer
Carmen A Peralta
Joseph J Saseen
Sidney C Smith
Laurence Sperling
Salim S Virani
Joseph Yeboah

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CardiologyHypercholesterolemiaPCSK9 InhibitorsAmerican Heart AssociationAnticholesteremic AgentsBiomarkersCardiovascular DiseasesEzetimibeHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMedication Therapy ManagementProprotein Convertase 9Risk AssessmentRisk Reduction BehaviorUnited StatesAnticholesteremic AgentsBiomarkersEzetimibeHydroxymethylglutaryl-CoA Reductase InhibitorsPCSK9 InhibitorsPCSK9 protein, humanProprotein Convertase 9ACC/AHA Clinical Practice Guidelinesbiomarkerscardiovascular diseasecholesterolcoronary artery calcium scorediabetes mellitusdrug therapyezetimibeGuidelineshydroxymethylglutaryl-CoA reductase inhibitors/statinshypercholesterolemiaLDL-cholesterollipidspatient compliancepharmacologicalprimary preventionproprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9) inhibitorsrisk assessmentrisk reduction discussionrisk treatment discussionsecondary prevention

Identifiers

PMID30423391

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.